尊敬的生物基领域的可持续先锋们 ： 扫描图片二维码报名 2026 DT新叶奖 · 邀请函 新年好！ 截止目前，已有 近50家 上市和代表性企业， 共60余份 新品报名参选2026DT新叶奖， 现公布四大奖项参选企业名单与参选产品 。 我们诚挚欢迎更多优秀企业积极报名参与，共同展现生物基领域的创新力量！ 报名截止时间：3月13日 2026第4届DT新叶奖（DT New Leaf Award）是由DT新材料、生物基能源与材料联合举办的全球化、专业性、综合性奖项，专注于生物基领域创新，被誉 为"生物基行业的奥斯卡"。 "新叶"，寓意蓬勃生机与可持续创新活力。DT新材料以此命名，旨在发掘生物基行业的先锋力量 —— 以可再生生物质为原料，用绿色技术突破传统局 限，驱动行业焕发低碳新生机，引领可持续发展新征程。 生物基能源与材料 Bio-based 2026 会务组 ▶ 获奖公布& 颁奖典礼 #第11届生物基大会 开幕式（5月21日，上海富悦大酒店） ⭕ 新叶奖 官网 一、 参选企业与产品 创新 材料奖 发掘生物基关键平台化合物和创新材料， 鼓励从"0"到"1"的源头创新 | 企业名称 | 参选产品 | | --- | ...

专题：《钱道》：对话上市公司掌门人 去年，华熙生物发文驳斥"透明质酸过时论""炮轰"券商研报一事，引发巨大争议，华熙生物董事长赵燕 在《钱道》栏目中表示，其实到现在也没后悔过，目的是让行业回到理性的时代。 专题：《钱道》：对话上市公司掌门人 去年，华熙生物发文驳斥"透明质酸过时论""炮轰"券商研报一事，引发巨大争议，华熙生物董事长赵燕 在《钱道》栏目中表示，其实到现在也没后悔过，目的是让行业回到理性的时代。 "我一直认为，它不是说一个新的物质出现，你就要把另外一个物质给它踩到脚底下，事实证明，今天 市场上，很少有人说重组胶原蛋白就是未来，它和透明质酸，它两者是协同的作用，现在要回归到科学 的本身来做产品，企业要重视研发，要有自己的底层逻辑，不要盲目地去内卷。"她说。 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 ...

Core Insights - The inclusion of "medical beauty services" in the CPI marks a significant shift for the industry, transitioning from a niche service to a recognized component of the national economic monitoring system [3][19] - The implementation of the new VAT regulations explicitly excludes profit-driven medical beauty institutions from tax exemptions, reinforcing their classification as commercial services and eliminating tax arbitrage opportunities [3][19] - These dual policy adjustments signify a transition from "wild growth" to "regulated development," fundamentally restructuring the competitive landscape and development logic of the medical beauty industry [3][19] Market Dynamics - The medical beauty market is experiencing "differentiated growth," with leading chain institutions achieving growth through refined operations, while smaller institutions face significant operational pressures [5][21] - In the first half of 2025, over 63% of medical beauty institutions reported revenue declines, with only 14% achieving growth; Q2 was particularly challenging, with 58% of institutions experiencing declines [5][21] - The average customer spending in the medical beauty industry dropped to 6,500 yuan, a 10% decrease year-on-year, while the frequency of consumer visits increased, indicating a trend towards more conservative spending among middle and high-income consumers [5][21] Consumer Trends - The trend of "popularization and down-market penetration" is becoming increasingly evident, with lower-tier cities emerging as new growth engines for the industry [6][22] - By 2025, the proportion of medical beauty institutions in third-tier cities and below increased from 30% in 2022 to 42%, with overall consumption growth reaching 22%, double that of first-tier cities [6][22] - Non-surgical light medical beauty projects have become the mainstream, accounting for over 53% of the market, with a market size of 227.9 to 258 billion yuan, driving industry growth [6][22] Regulatory Environment - The simultaneous implementation of the CPI inclusion and new VAT regulations represents a policy "one-two punch" for the regulated development of the medical beauty industry, establishing its commercial consumption attributes [8][24] - This regulatory shift has eliminated the "gray area" label that has long plagued the industry, with the CPI now monitoring price fluctuations and consumption scale as part of national economic management [9][25] - The combination of these policies is transforming the identity of the medical beauty industry from "marginal service" to "mainstream consumption," laying the groundwork for its regulated development [10][26] Competitive Landscape - The regulatory changes are leading to a "good money driving out bad money" scenario, where compliant institutions benefit from favorable conditions while non-compliant ones face significant operational challenges [11][27] - Over 18,000 non-compliant institutions were shut down in 2025, and more than 320 violators had their licenses revoked, indicating the effectiveness of ongoing regulatory measures [11][27] - The market is shifting from a seller's market to a buyer's market, with price wars becoming a primary strategy for smaller institutions competing for customers [6][22] Industry Evolution - The medical beauty industry is transitioning from an upstream-dominated model to one focused on terminal capabilities, with an emphasis on differentiation and scale as core competitive advantages [12][28] - Upstream companies are shifting their focus from licensing to product innovation, as competition intensifies and profit margins normalize [13][29] - The entry of public hospitals into the medical beauty sector is becoming a new variable, with a significant increase in the number of public hospitals establishing medical beauty departments [14][30] Consumer Behavior - Consumers are becoming more rational, shifting from a focus on appearance changes to daily anti-aging maintenance, with increased demands for product safety and institutional compliance [15][31] - This rationalization is driving industry upgrades, as institutions move towards standardized solutions that combine products, medical expertise, and post-operative management [15][31] - The transparency of industry information is improving, allowing consumers to compare the overall value of different institutions, which is pushing prices towards greater fairness [15][31]

头部医美机构春节消费情况交流 20260223 摘要 2026 年初线下医美终端机构营收呈现波动，1 月同比增长 11%，2 月 受春节影响同比下降 4%，前两月整体增长约 6%，客流量上升 10%， 但客单价持续下降。 轻医美占比提升导致单价下降，机构需引进高利润产品或设备以保持利 润空间。监管趋严促进合规，支持新产品审批，增值税增加压力但可通 过合理抵扣缓解。 非手术项目占比持续提升至 66%-70%，光电皮肤类项目占比稳定在 40%-45%，注射类项目不断增加。光电皮肤设备市场在紧致抗衰方面 需求较高，但客单价可能持续下降。 注射类产品线将显著增长，玻尿酸、新型肉毒素、重组胶原蛋白等不断 推出新产品。机构积极布局 OEM 代工贴牌定制，以降低成本并提高利 润率。 玻尿酸市场中，进口高端品牌仍受欢迎，但 OEM 定制贴牌玻尿酸逐渐 成为主推项目，增速显著。传统品牌增速放缓，差异化新品牌表现出色。 重组胶原蛋白市场增速显著，预计 2026 年保持强劲增长。锦波公司占 据重要地位，但新进入者将形成冲击，新产品上市将扩大市场份额。 肉毒素产品线稳定增长，新款肉毒素获批上市有望继续推动销量增长。 童颜针市场竞争稳 ...

智通财经APP获悉，国金证券发布研报称，奢侈品、高端香化、高端零售业绩修复加速，高净值人群消 费恢复或是高端消费改善的主要原因。该行认为，当前中国高端消费筑底效应已经展现，短期内高端消 费修复需依靠高净值人群的财富效应与针对中产的政策刺激。中长期看，需关注收入和就业的系统性改 善、房地产的企稳回升，以及财富效应从高净值人群向中产的扩散节奏。高端消费实际需求改善+供给 相对稀缺+政策效果强，重点推荐免税、黄金珠宝行业。 国金证券主要观点如下： 免税：低基数，强政策红利，高端消费修复，有望带动免税行业重回增长 免税是进口化妆品、奢侈品等高档消费品流通的重要渠道，将极大受益于高端消费恢复。海南自由贸易 港正式启动封关，有望对海南本地以及全国的免税业务产生明显的影响，叠加高端消费复苏趋势持续演 绎，影响逻辑有望超预期。此外，日本旅游热度下滑后，海南成为新热门目的地。去哪儿旅行、携程等 平台数据显示，截至2月初，春节假期目的地为海南的日均机票订单量同比增长超45%。 中国中免：公司基本面回暖，从内需看，高端消费的恢复是免税行业复苏的基础，免税行业存在整体性 机会；从外需看，入境游客的消费潜力，并未被市场充分认识，预期中 ...

Group 1: Medical Aesthetics Industry - The Chinese medical aesthetics market is expected to reach nearly 370 billion yuan by 2025, with a compound annual growth rate (CAGR) of approximately 10% projected until 2030, potentially reaching 600 billion yuan [2][8][36] - The trend of "self-pleasure consumption" is prominent, with about 50% of users indicating that the reason for choosing medical aesthetics is that "becoming beautiful makes them happier" [8][11][15] - The consumer demographic is shifting towards younger individuals, with the proportion of users under 25 years old increasing from 26% in 2022 to 35% by 2025 [20][22][36] - Light medical aesthetics are becoming mainstream, accounting for 52% of the market in 2022, with a growing preference for non-invasive procedures [16][17][36] - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, potentially reaching 114.5 billion yuan [8][45] Group 2: Beauty Industry - The retail sales of cosmetics in China are projected to grow at a CAGR of approximately 9% from 2016 to 2024, with a moderate recovery expected in 2025 [3][9] - The trend of "self-gifting" is becoming the primary scenario for beauty consumption, reflecting the strengthening of "self-pleasure consumption" [3][8] - The cosmetics raw materials market is expected to grow from 1147.8 billion yuan in 2019 to 1603.9 billion yuan by 2024, with a CAGR of 6.9% [3][9] - The ODM (Original Design Manufacturer) industry for cosmetics is projected to reach 62.29 billion yuan by 2025, with domestic brands gaining market share [3][9] Group 3: Related Companies on the Beijing Stock Exchange - Companies such as Jinbo Biological, which leads in recombinant collagen medical devices and is entering the functional skincare market, are expected to benefit from the ongoing growth in the beauty consumption sector [3][8] - Bawei Co., which provides ODM services for domestic and international cosmetic brands, is also positioned to gain from the industry's expansion [3][8] - Leading companies in cosmetic raw materials, such as Weiqi Technology and Jiakai Biological, are well-placed to capitalize on the industry's growth [3][8]

Group 1: Medical Aesthetics Industry - The Chinese medical aesthetics market is expected to reach nearly 370 billion by 2025, with a high growth outlook for the recombinant collagen segment [2][35] - The trend of younger consumers in medical aesthetics is evident, with light medical aesthetics gradually becoming mainstream, accounting for 52% of the market in 2022 [7][12] - Approximately 50.90% of users choose medical aesthetics because "becoming beautiful can make oneself happier," indicating a strong emotional value associated with beauty [4][8] Group 2: Beauty Industry - The retail sales of cosmetics in China are projected to grow at a CAGR of about 9% from 2016 to 2024, with domestic brands expected to maintain growth momentum [2][3] - The Chinese cosmetics market is entering a phase of high-quality development, with trends leaning towards scientific beauty and Eastern philosophies [3][19] - The market for cosmetic raw materials is expected to grow from 1147.80 billion in 2019 to 1603.90 billion by 2024, with a CAGR of 6.9% [2][3] Group 3: Related Companies on the Beijing Stock Exchange - Companies such as Jinbo Biological, which leads in recombinant human collagen medical devices, and Bawei Co., which provides ODM services for domestic and international cosmetic brands, are expected to benefit from the ongoing beauty consumption boom [2][3] - The market for functional skincare products is also seeing new entrants, with companies like Jinbo Biological expanding into this segment [2][3] - The beauty industry is experiencing a transformation driven by technological innovations, including synthetic biology and the application of new materials [2][3]

Investment Rating - The report gives a "Buy" rating for Dongxing Medical [5] Core Viewpoints - Dongxing Medical is positioned as a micro-invasive surgical platform company with diversified layouts that promote growth. The company focuses on the anastomosis device industry chain and is gradually expanding into other micro-invasive surgical products, aiming to establish itself as a platform enterprise in medical devices [3][12] - The company plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., which has obtained 58 medical device registration certificates, enhancing its medical device platform and facilitating synergistic development [3][12] - The company has a concentrated shareholding structure and a professional management team, with expected revenue growth driven by product upgrades and cost control [3][12] Summary by Sections 1. Company Overview - Dongxing Medical has diversified its business since its establishment in 2001, transitioning from an agency model to a medical device manufacturer. The company has completed several acquisitions to integrate its supply chain, including the acquisition of Weike Medical and Zihang Precision, which closed the anastomosis device industry chain [12][19] - The company has a strong cash position, with cash and cash equivalents reaching 1.2 billion yuan, supporting future acquisitions [30][32] 2. Anastomosis Device Market - The anastomosis device market in China is expected to reach 9.82 billion yuan by 2024, with a compound annual growth rate (CAGR) of 8.1% from 2019 to 2024. The electric laparoscopic anastomosis device market is projected to grow significantly, with a CAGR of 44.4% during the same period [49][52] - The report indicates that the impact of centralized procurement on pricing has reached a turning point, with price adjustments stabilizing and the industry entering a phase of steady growth as penetration rates increase [54][55] 3. New Surgical Products - The company is expanding its product line to include ultrasonic knives, with a market size in the tens of billions. The domestic market for ultrasonic knives is rapidly increasing due to the rise in domestic production rates [5][12] - The company is also collaborating with Shanghai Jiao Tong University to develop synthetic biological materials, which are expected to be applied in serious medical fields such as hemostasis and scar repair, adding another growth point [5][12] 4. Financial Forecast and Valuation - The company forecasts revenues of 379 million yuan, 445 million yuan, and 512 million yuan for 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be -37 million yuan, 94 million yuan, and 121 million yuan for the same years [5][8] - The report estimates a price-to-earnings (PE) ratio of 29x for 2026 based on the closing price on January 16, 2026 [5][8]

Core Insights - The beauty industry is undergoing a significant transformation as consumers prioritize product ingredients and efficacy over marketing narratives and brand stories [1][2] - The competition among companies is shifting from traditional marketing to a focus on scientific validation and technical authority, particularly regarding core ingredients [1][3] Group 1: Industry Dynamics - The battle for defining the "ingredient king" is exemplified by the prolonged conflict between Huaxi Biological and Juzhi Biological over recombinant collagen, highlighting the industry's shift towards scientific discourse [1][2] - Companies are increasingly engaged in disputes over intellectual property and scientific narratives, as seen in the conflict between medical company Aierfu and skincare brand Zhanmeiya, which revolves around the storytelling of scientific advancements [3] Group 2: Market Competition - The competition for established, cash-generating scientific products is illustrated by the dispute between Shuiyang Co. and Ruoyu Chen over the agency rights for the Spanish brand "Mestique," which has shown remarkable growth in the Chinese market [5][6] - The financial performance of companies varies significantly, with some experiencing revenue growth alongside increased R&D spending, while others face declining revenues despite high R&D investments [6][7] Group 3: Consumer Behavior - A significant shift in consumer preferences is noted, with 58.8% of consumers prioritizing product ingredients in their purchasing decisions, indicating a growing demand for transparency and efficacy [15][21] - The rise of the "ingredient party" has led to increased scrutiny of product claims, pushing companies to provide credible testing reports and validate their ingredients [15][21] Group 4: Future Trends - The beauty industry's future is marked by a "scientific arms race," with brands striving to establish their authority in scientific research and ingredient validation [8][16] - Companies are exploring unique natural ingredients and integrating skincare with makeup, reflecting a trend towards holistic beauty solutions [20][21]

Core Viewpoint - Guangdong Province aims to enhance the bio-manufacturing industry, targeting a total output value of approximately 500 billion yuan by 2027 and reaching a trillion yuan scale by 2035, focusing on key areas such as non-grain utilization, medical beauty raw materials, microbial proteins, and green processes in biopharmaceuticals [2][3][4]. Group 1: Policy Measures and Goals - The action plan specifies the development goals for the bio-manufacturing industry in Guangdong, aiming for a total output value of around 500 billion yuan by 2027 and a trillion yuan scale by 2035 [2][3]. - The measures address key bottlenecks in bio-manufacturing, including the need for improved standards and ecosystem development [4][6]. Group 2: Key Initiatives - The policy outlines detailed initiatives to tackle issues such as an incomplete industrial chain and lagging standard system construction, emphasizing the establishment of a comprehensive bio-manufacturing industry standard system [6]. - It encourages the establishment of innovation platforms and supports the construction of transformation bases for innovative achievements, promoting technology transfer and application [6]. Group 3: Focus Areas for Development - The measures focus on core technology breakthroughs, including strains, enzyme preparations, and reactors, as well as high-end platform construction and targeted R&D mechanisms [7]. - The policy emphasizes the importance of building a robust standard system that includes both domestic and international standards, facilitating market access and internationalization [7]. Group 4: Applications in Bio-Manufacturing - The initiative aims to advance non-grain bio-based materials, medical beauty products, and "new food" categories, promoting the use of microbial proteins and plant-based proteins [8][9]. - In the pharmaceutical sector, the policy encourages the application of bio-manufacturing in green process development for biopharmaceuticals and the synthesis of effective components from traditional Chinese medicine [9]. Group 5: Internationalization Strategies - The policy outlines strategies for internationalization, including aligning with international standards organizations and expanding overseas markets through e-commerce and overseas warehouses [10]. - It emphasizes the importance of attracting key domestic and international enterprises and high-end R&D institutions to build a global resource collaboration network [10]. Group 6: Regional Development and Innovation - Guangdong Province implements a "dual-core drive" strategy, focusing on Guangzhou and Shenzhen to accelerate the development of the bio-manufacturing industry in the Greater Bay Area [11]. - The policy supports the establishment of a comprehensive support system for bio-manufacturing, covering research, pilot testing, and industrialization [11].